company background image
TMDX

TransMedics Group NasdaqGM:TMDX Stock Report

Last Price

US$60.03

Market Cap

US$1.9b

7D

-2.8%

1Y

163.9%

Updated

08 Dec, 2022

Data

Company Financials +
TMDX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

TMDX Stock Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

TransMedics Group, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TransMedics Group
Historical stock prices
Current Share PriceUS$60.03
52 Week HighUS$64.36
52 Week LowUS$10.00
Beta1.61
1 Month Change10.15%
3 Month Change12.44%
1 Year Change163.87%
3 Year Change241.47%
5 Year Changen/a
Change since IPO168.47%

Recent News & Updates

Recent updates

Is TransMedics Group (NASDAQ:TMDX) Weighed On By Its Debt Load?

Jun 12
Is TransMedics Group (NASDAQ:TMDX) Weighed On By Its Debt Load?

Industry Analysts Just Upgraded Their TransMedics Group, Inc. (NASDAQ:TMDX) Revenue Forecasts By 26%

May 08
Industry Analysts Just Upgraded Their TransMedics Group, Inc. (NASDAQ:TMDX) Revenue Forecasts By 26%

The Consensus EPS Estimates For TransMedics Group, Inc. (NASDAQ:TMDX) Just Fell Dramatically

Feb 28
The Consensus EPS Estimates For TransMedics Group, Inc. (NASDAQ:TMDX) Just Fell Dramatically

Is TransMedics Group (NASDAQ:TMDX) Using Debt Sensibly?

Jan 03
Is TransMedics Group (NASDAQ:TMDX) Using Debt Sensibly?

Health Check: How Prudently Does TransMedics Group (NASDAQ:TMDX) Use Debt?

Aug 30
Health Check: How Prudently Does TransMedics Group (NASDAQ:TMDX) Use Debt?

When Will TransMedics Group, Inc. (NASDAQ:TMDX) Become Profitable?

Apr 01
When Will TransMedics Group, Inc. (NASDAQ:TMDX) Become Profitable?

John Carey Is The Vice President of Operations of TransMedics Group, Inc. (NASDAQ:TMDX) And They Just Sold 100% Of Their Shares

Mar 14
John Carey Is The Vice President of Operations of TransMedics Group, Inc. (NASDAQ:TMDX) And They Just Sold 100% Of Their Shares

Is TransMedics Group (NASDAQ:TMDX) Using Debt In A Risky Way?

Mar 08
Is TransMedics Group (NASDAQ:TMDX) Using Debt In A Risky Way?

If You Had Bought TransMedics Group (NASDAQ:TMDX) Shares A Year Ago You'd Have Earned 31% Returns

Feb 05
If You Had Bought TransMedics Group (NASDAQ:TMDX) Shares A Year Ago You'd Have Earned 31% Returns

Shareholder Returns

TMDXUS Medical EquipmentUS Market
7D-2.8%-1.1%-2.8%
1Y163.9%-20.9%-19.6%

Return vs Industry: TMDX exceeded the US Medical Equipment industry which returned -22.9% over the past year.

Return vs Market: TMDX exceeded the US Market which returned -21.2% over the past year.

Price Volatility

Is TMDX's price volatile compared to industry and market?
TMDX volatility
TMDX Average Weekly Movement10.4%
Medical Equipment Industry Average Movement8.9%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: TMDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: TMDX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998148Waleed Hassaneinhttps://www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers.

TransMedics Group, Inc. Fundamentals Summary

How do TransMedics Group's earnings and revenue compare to its market cap?
TMDX fundamental statistics
Market CapUS$1.92b
Earnings (TTM)-US$42.18m
Revenue (TTM)US$71.75m

26.7x

P/S Ratio

-45.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TMDX income statement (TTM)
RevenueUS$71.75m
Cost of RevenueUS$20.20m
Gross ProfitUS$51.56m
Other ExpensesUS$93.73m
Earnings-US$42.18m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.32
Gross Margin71.85%
Net Profit Margin-58.78%
Debt/Equity Ratio31.2%

How did TMDX perform over the long term?

See historical performance and comparison